Shots:
- Formycon & Zydus Lifescience has reported that the pivotal Dahlia PK study of FYB206, a biosimilar version of Keytruda (pembrolizumab), has met its 1EP
- The multicenter PK study showed bioequivalence of FYB206 (pembrolizumab) to Keytruda
- Zydus Lifesciences has exclusively in-licensed FYB206, a proposed biosimilar to Keytruda (pembrolizumab), from Formycon for the US and Canada
Ref: Zydus Lifesciences | Image: Zydus Lifesciences and Formycon | Press Release
Related News: Zydus Lifesciences Launches Tishtha (Biosimilar, Opdivo) in India
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
